This technology allows phenotypic screening to discover new compounds and new targets for complex diseases, such as neurodegenerative diseases and cancer
HCS main assets for active cosmetic ingredients
Confirming the efficacy of nutraceuticals and functional food is a key for the development of new compounds. High content in vitro assays play a role in researching and developing new actives ingredients dedicated to human and animals food.
Phenotypic screening by High Content Screening allows analysing toxic events, as genotoxicity, hepatotoxicity, neurotoxicity or cardiotoxicity at the early stage of research.
BIOMIMESYS® 3D technology is a natural HA-based scaffold to better mimic the tissue microenvironment and provide more predictive tools for drug development. The BIOMIMESYS® products are formed by crosslinking reaction of hydrosoluble modified hyaluronic acid and others matrix components with ADH (adipic acid dihydrazide), to mimic the extracellular matrix (ECM). Depending on the organ, ECM components vary and are present in different proportions, allowing a more or less dense and compact cellular environment. BIOMIMESYS® 3D technology allows us to reproduce the cell microenvironment of each organ.
Click here to get more information!
The 16th SFBMEC congress was held last week in Reims: Elodie and Zied attended the meeting to be aware of the last trends in extracellular matrix (ECM) research and industry and medical applications. And they Read more…
Our CDO Grégory was at the Fluorescence Microscopy Worskshop last week at Pasteur Paris to discover new usages and technologies in microscopy. Even if this event was mainly focused on super resolution microscopy, many tips Read more…
Our study director Elodie really enjoyed Vitafoods last week in Geneva, and the welcome she had on the different booths she visited along the three days! The show was very impressive, with a wide variety Read more…
Next week HCS Pharma will be present at SFBMEc Reims (15th-17th May). We will present a poster about the influence of BIOMIMESYS® hydroscaffold composition and stiffness on the 3D culture of breast cancer cells. The Read more…
You should know Science Exchange, the world’s leading and most secure platform for outsourced research, providing large R&D organizations with the fastest path from discovery through development and commercialization. Now, we are very proud to Read more…
We will be at Vitafoods Europe 2019 next week in Geneva. It’s a big opportunity to discover our services in nutraceticals and dermocosmetology. This year Vitafoods Europe will focus on sustainability, it’s why we will Read more…
Many skin diseases, including psoriasis and basal cell carcinoma, are associated with microbial dysbiosis characterized by reduced C. acnes prevalence. C. acnes is a facultative anaerobic bacterium that is frequently found on the human skin. Read more…
The California Cruelty-Free Cosmetics Act, SB 1249, was introduced in the California State Legislature. On Jan. 1st, 2020 the bill will prohibit the sale of animal-tested cosmetics in the state. The European Union ended importation Read more…
Since 2 years, we saw AI (Artificial Intelligence) spreading in more and more domains, sometime presented as the “panacée” of all problems. In healthcare, and especially in drug discovery, many announces are done but, to Read more…
The annual SCMC congress (Société Cerveau et Maladies Cérébrovasculaires – Brain and Cerebrovascular diseases Society) took place in Lille last week, in the Faculty of Medecine. The congress was organized in three sessions. The first Read more…
Wound healing is a crucial physiological process rehabilitating the unity of the skin barrier. Inflammation in wound healing is a weapon with two edges. It is indispensable but must be strongly regulated both temporally and Read more…
Last week HCS Pharma team enjoyed Forum Labo Paris! We enjoyed it twofold because : we won our booth on the Lab’StartUp Village, in the heart of the fair. It gave us the opportunity to Read more…
We will be happy to meet you at In-cosmetics Global at Porte de Versailles this week from 2nd-4th of April (https://www.in-cosmetics.com/global/) and to present you our multiplex offer (based on in vitro automated cell Imaging) Read more…
Our CEO, Nathalie, has presented company strategy in front of many investors at Start West event in Rennes. She explained especially why our next fund rising is mandatory to develop internationally our exclusive BIOMIMESYS® products. Read more…
Véronique De Conto, doctorante chez HCS Pharma, présentera ce jeudi 28 mars à Lille, au congrès annuel de la Société Cerveau et Maladies Cérébrovasculaires, le développement d’un modèle cérébral en 3 dimensions incluant le microenvironnement Read more…
The status of Young Innovative Company (JEI) recognize young companies very active in R&D. this distinction is given by the french ministry of research.
Led by Pr Bertrand Cariou, director of l’institut du thorax*, the project aims at improving the management of hypercholesterolemia by identifying new markers in cardiovascular risk and new targets of LDL-cholesterol metabolism, which plays a central role in the development and progression of cardiovascular diseases.
HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
See on map
HCS Pharma – Site de Rennes
Biopole
6 Rue Pierre Joseph Colin
35000 RENNES
See on map
+33 769 999 137
Only for customers please, if you have another interest use the form contact.